STA Pharmaceutical, a WuXi AppTec company, has signed an oligonucleotide synthesis collaboration agreement with biopharmaceutical company, Regulus Therapeutics, for research and mid-scale non-GMP/cGMP manufacturing.
Sign agreement
“We are excited to establish a high quality oligonucleotide R&D and manufacturing technology and capability platform, and it's a great honour to work with an innovative, pioneering company, such as Regulus. This partnership will allow STA to expedite Regulus’ oligonucleotide therapeutics programmes into the clinic, and eventually, to patients,” said Dr Minzhang Chen, CEO of STA Pharmaceutical. “Through our newly established global quality oligonucleotide platform, we strive to make life-saving oligonucleotide therapeutics more affordable and available to patients worldwide.”
“By partnering with a well-respected, world-class organization like WuXi STA, we gain their commitment to support our long-term development and commercialisation goals,” said Jay Hagan, President and CEO of Regulus.
As per the terms of the agreement, STA will become a new strategic development and manufacturing partner for Regulus’ preclinical and clinical programmes of microRNA-targeting drugs used to treat a broad range of diseases. Regulus will provide STA with expertise, technical know-how, and training in the field of oligonucleotide scale-up.